Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 17, 2009, Pages 5261-5265

  Woodrow, Michael D ^a   Ballantine, Stuart P ^a   Barker, Michael D ^a   Clarke, Beth J ^a   Dawson, John ^a   Dean, Tony W ^a   Delves, Christopher J ^a   Evans, Brian ^a   Gough, Sharon L ^a   Guntrip, Steven B ^a   Holman, Stuart ^a   Holmes, Duncan S ^a   Kranz, Michael ^a   Lindvaal, Mika K ^a   Lucas, Fiona S ^a   Neu, Margarete ^a   Ranshaw, Lisa E ^a   Solanke, Yemisi E ^a   Somers, Don O ^a   Ward, Peter ^a   Wiseman, Joanne O ^a   more..

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Crystallography; PDE4 inhibitors; Quinoline; SAR

Indexed keywords

GSK 256066; LIPOPOLYSACCHARIDE; PHOSPHODIESTERASE IV INHIBITOR; QUINOLINE DERIVATIVE; ROFLUMILAST; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ARTICLE; CRYSTALLOGRAPHY; DRUG ACTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN CELL; MONONUCLEAR CELL; NONHUMAN; RAT;

ADMINISTRATION, INHALATION; ANIMALS; ANTI-INFLAMMATORY AGENTS; BINDING SITES; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; HUMANS; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; PHOSPHODIESTERASE 4 INHIBITORS; PHOSPHODIESTERASE INHIBITORS; QUINOLINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA;

EID: 68349150615     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.04.012     Document Type: Article

References (21)

1. Houslay M.D., Schafer P., and Zhang K.Y.J. Drug Discovery Today 10 (2005) 1503
2. Soto F.J., and Hanania N.A. Curr. Opin. Pulm. Med. 11 (2005) 129
3. For recent reviews see:. McKenna J.M., and Muller G.W. Cyclic Nucleotide Phosphodiesterases Health Disease (2007) 667
4. Dyke H.J. Exp. Opin. Ther. Patents 17 (2007) 1183
5. Smith V.B., and Spina D. Curr. Opin. Invest. Drugs 6 (2005) 1136
6. Horowski R., and Sastre-Y-Hernandez M. Curr. Ther. Res. 38 (1985) 23
7. Spina D. Drugs 63 (2003) 2575
8. Hogger P. Curr. Opin. Pulm. Med. 9 (2003) 1
9. Mollmann H., Wagner M., Meibohm B., Hochhaus G., Barth J., Stockmann R., Krieg M., Weisser H., Falcoz C., and Derendorf H. Eur. J. Clin. Pharmacol. 53 (1998) 459
10. Kranz, M.; Lindvall, M. K.; Hamblin, J. N.; Jones, P. S.; Neu, M. Y.; Somers, D. O. in preparation.
11. Lunniss C.J., Cooper A.W.J., Eldred C.D., Kranz M., Lindvall M., Lucas F.S., Neu A., Preston A.G.S., Ranshaw L.E., Redgrave A.J., Robinson J.E., Shipley T.J., Solanke Y.E., Somers D.O., and Wiseman J.O. Bioorg. Med. Chem. Lett. 19 (2009) 1380
12. Methods as described in Ref. 15 of Hamblin, J. N.; Angell, T. D. R.; Ballantine, S. P.; Cook, C. M.; Cooper, A. W. J.; Dawson, J.; Delves, C. J.; Jones, P. S.; Lindvall, M.; Lucas, F. S.; Mitchell, C. J.; Neu, M. Y.; Ranshaw, L. E.; Solanke, Y. E.; Somers, D. O.; Wiseman J. O. Bioorg. Med. Chem. Let., 2008, 14, 4237, except compound 4 was soaked at 1 mM for ∼1 day. Compound 4 was refined with partial occupancy due to incomplete substitution of an Arsenate species that normally occupies the inhibitor binding site and is derived from the crystallisation conditions (Xu, R. X.; Hassell, A. M.; Vanderwall, D.; Science 2000, 288, 1822). The final R-factor achieved for complex 4 following structure refinement was 20.5% (Rfree = 25.0%) and the coordinates deposited in the PDB as entry 3GWT. Note that red crosses in Figures 1 and 2 show the position of water molecules.
13. 1H NMR analysis.
14. Schopfer U., and Schlapbach A. Tetrahedron 57 (2001) 3069
15. Analysis of CCDC X-ray structures for bis-aryl sulfones show a strong preference for a 90° torsional angle whereas the sulfides show no torsional preference.
16. Mignon P., Loverix S., and Geerlings P. Chem. Phys. Lett. 401 (2005) 40-46
17. The ability of compounds to inhibit catalytic activity at PDE4B (human recombinant), PDE3 (from bovine aorta) and PDE5 (human recombinant) was determined by Scintillation Proximity Assay (SPA) in 96-well format as described in WO2004024728. Values are means of at least two experiments (n shown in parentheses).
18. Kwong F.Y., and Buchwald S.L. Org. Lett. 5 (2003) 793 Copper catalysed conditions were preferred for products with ester functionality, palladium was used in all other cases
19. Inhibition of LPS induced TNF-α production from isolated human peripheral blood mononuclear cells (PBMC) or human whole blood using IGEN technology was carried out as described in patent WO2007036733. Values are means of at least four experiments (n shown in parentheses).
20. Nials, A.T. in preparation.
21. Tralau-Stewart, C.J. in preparation.